The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so.
暂无分享,去创建一个
D. Kell | S. Oliver | P. Dobson | E. Bilsland
[1] H. Schwan. Electrical properties of tissue and cell suspensions. , 1957, Advances in biological and medical physics.
[2] P. Seeman,et al. The membrane actions of anesthetics and tranquilizers. , 1972, Pharmacological reviews.
[3] Alan Mellors,et al. The haldane relationship enzymes & equilibrium , 1976 .
[4] A. Cornish-Bowden. Fundamentals of Enzyme Kinetics , 1979 .
[5] V A Levin,et al. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.
[6] D. Kell,et al. The passive electrical properties of biological systems: their significance in physiology, biophysics and biotechnology. , 1987, Physics in medicine and biology.
[7] Douglas B. Kell,et al. Dielectric permittivity of microbial suspensions at radio frequencies: a novel method for the real-time estimation of microbial biomass , 1987 .
[8] T. Keleti. Basic Enzyme Kinetics , 1988 .
[9] A. Fairlamb,et al. Trypanothione is the primary target for arsenical drugs against African trypanosomes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[10] T. Walle,et al. Stereoselective uptake of atenolol into storage granules isolated from PC12 cells. , 1989, The Journal of pharmacology and experimental therapeutics.
[11] B. Dujon,et al. The complete DNA sequence of yeast chromosome III , 1992, Nature.
[12] A. Fairlamb,et al. Arsenical-resistant trypanosomes lack an unusual adenosine transporter , 1993, Nature.
[13] D. Thwaites,et al. Transepithelial glycylsarcosine transport in intestinal Caco-2 cells mediated by expression of H(+)-coupled carriers at both apical and basal membranes. , 1993, The Journal of biological chemistry.
[14] Alan Chalmers,et al. What is this thing called science? - an assessment of the nature and status of science and its methods (2. ed.) , 1977, UQP nonfiction.
[15] B. Barrell,et al. Life with 6000 Genes , 1996, Science.
[16] R. Moellering,et al. Antimicrobial-drug resistance. , 1996, The New England journal of medicine.
[17] A. Fersht. Structure and mechanism in protein science , 1998 .
[18] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[19] P. Brick,et al. Structural basis for the inhibition of firefly luciferase by a general anesthetic. , 1998, Biophysical journal.
[20] V. Ganapathy,et al. Cloning and Functional Characterization of a Potential-sensitive, Polyspecific Organic Cation Transporter (OCT3) Most Abundantly Expressed in Placenta* , 1998, The Journal of Biological Chemistry.
[21] M. Trush,et al. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. , 1998, Biochemical and biophysical research communications.
[22] R. Kaminsky,et al. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. , 1999, Science.
[23] V. Sasseville,et al. A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.
[24] Y. Kanai,et al. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. , 1999, Molecular pharmacology.
[25] Transport of [3H]losartan across isolated perfused rabbit proximal tubule. , 1999, The Journal of pharmacology and experimental therapeutics.
[26] T. Andersson,et al. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. , 1999, The Journal of pharmacology and experimental therapeutics.
[27] E. Holtzman,et al. Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). , 1999, Biochemical and biophysical research communications.
[28] D. Gründemann,et al. Selective substrates for non-neuronal monoamine transporters. , 1999, Molecular pharmacology.
[29] Y. Kanai,et al. Transport of ochratoxin A by renal multispecific organic anion transporter 1. , 1998, The Journal of pharmacology and experimental therapeutics.
[30] S. Kano. [Drug resistant malaria]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.
[31] M. Rowland,et al. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. , 1999, The Journal of pharmacology and experimental therapeutics.
[32] M. Lazdunski,et al. Inhalational anesthetics activate two-pore-domain background K+ channels , 1999, Nature Neuroscience.
[33] V. Ganapathy,et al. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. , 2000, Biochimica et biophysica acta.
[34] R. Evers,et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.
[35] T. Cihlar,et al. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. , 2000, The Journal of pharmacology and experimental therapeutics.
[36] H. Saito,et al. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. , 2000, The Journal of pharmacology and experimental therapeutics.
[37] K. Bleasby,et al. The organic cation transporter OCT2 mediates the uptake of β‐adrenoceptor antagonists across the apical membrane of renal LLC‐PK1 cell monolayers , 2000, British journal of pharmacology.
[38] M. Sanguinetti,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[39] I. Rusyn,et al. Diphenyleneiodonium sulfate, an NADPH oxidase inhibitor, prevents early alcohol-induced liver injury in the rat. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[40] Y. Kanai,et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. , 2001, Molecular pharmacology.
[41] Marilyn Roberts,et al. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance , 2001, Microbiology and Molecular Biology Reviews.
[42] D B Kell,et al. Genomic computing. Explanatory analysis of plant expression profiling data using machine learning. , 2001, Plant physiology.
[43] K. Jung,et al. Characterization of ochratoxin A transport by human organic anion transporters. , 2001, Life sciences.
[44] J. Carlton,et al. Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. , 2001, Current opinion in microbiology.
[45] H. D. de Koning. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. , 2001, Molecular pharmacology.
[46] T. Ideker,et al. A new approach to decoding life: systems biology. , 2001, Annual review of genomics and human genetics.
[47] J. Markowitz,et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. , 2002, Life sciences.
[48] W. Crumb,et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.
[49] G. Tegos,et al. Multidrug Pump Inhibitors Uncover Remarkable Activity of Plant Antimicrobials , 2002, Antimicrobial Agents and Chemotherapy.
[50] Yuichi Sugiyama,et al. Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.
[51] H. Kitano,et al. Computational systems biology , 2002, Nature.
[52] A. Enomoto,et al. Role of human organic anion transporter 4 in the transport of ochratoxin A. , 2002, Biochimica et biophysica acta.
[53] A. Enomoto,et al. Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[54] T. Buzan. How to Mind Map , 2002 .
[55] H. Kitano. Systems Biology: A Brief Overview , 2002, Science.
[56] P. Neuvonen,et al. Drug-related deaths in a university central hospital , 2002, European Journal of Clinical Pharmacology.
[57] M. Yasui,et al. Aquaporin Water Channels , 2004 .
[58] Y. Tanigawara,et al. Interaction of digoxin with antihypertensive drugs via MDR1. , 2002, Life sciences.
[59] C. Clayton,et al. Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei , 2002, Molecular microbiology.
[60] H. Endou,et al. Characterization of Methotrexate Transport and Its Drug Interactions with Human Organic Anion Transporters , 2002, Journal of Pharmacology and Experimental Therapeutics.
[61] Ronald W. Davis,et al. Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.
[62] Guri Giaever,et al. A chemical genomics approach to understanding drug action. , 2003, Trends in pharmacological sciences.
[63] L. Hood. Systems biology: integrating technology, biology, and computation , 2003, Mechanisms of Ageing and Development.
[64] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[65] M. Ouellette,et al. Functional Cloning of the Miltefosine Transporter , 2003, Journal of Biological Chemistry.
[66] Andreas Rolfs,et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins , 2004, Pflügers Archiv.
[67] Yu Zong Chen,et al. Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.
[68] Matthew R. Redinbo,et al. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme , 2003, Nature Structural Biology.
[69] B. Fermini,et al. The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.
[70] J. Sands. Mammalian urea transporters. , 2003, Annual review of physiology.
[71] M. Romero,et al. The SLC4 family of HCO3− transporters , 2004, Pflügers Archiv.
[72] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[73] Peter J. Meier,et al. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.
[74] G. Burckhardt,et al. Transport of cimetidine by flounder and human renal organic anion transporter 1. , 2003, American journal of physiology. Renal physiology.
[75] W. Tanner,et al. Specific lipid requirements of membrane proteins--a putative bottleneck in heterologous expression. , 2003, Biochimica et biophysica acta.
[76] H. Vromans,et al. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. , 2003, International journal of pharmaceutics.
[77] W. Sadee,et al. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[78] N. Franks,et al. The TREK K2P channels and their role in general anaesthesia and neuroprotection. , 2004, Trends in pharmacological sciences.
[79] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[80] Gregory W. Kauffman,et al. Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.
[81] S. Sasaki,et al. Molecular mechanisms and drug development in aquaporin water channel diseases: aquaporin superfamily (superaquaporins): expansion of aquaporins restricted to multicellular organisms. , 2004, Journal of pharmacological sciences.
[82] Claude Roques,et al. Correlation Between Oral Drug Absorption in Humans, and Apparent Drug Permeability in TC-7 Cells, A Human Epithelial Intestinal Cell Line: Comparison with the Parental Caco-2 Cell Line , 1998, Pharmaceutical Research.
[83] S. Ekins. Predicting undesirable drug interactions with promiscuous proteins in silico. , 2004, Drug discovery today.
[84] B. Palsson,et al. The evolution of molecular biology into systems biology , 2004, Nature Biotechnology.
[85] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.
[86] Seeing the light: protein theories of general anesthesia. 1984. , 2004, Anesthesiology.
[87] Antony D'Emanuele,et al. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[88] D. Kell,et al. On the dielectrically observable consequences of the diffusional motions of lipids and proteins in membranes , 1985, European Biophysics Journal.
[89] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[90] Bryan L Roth,et al. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. , 2004, Pharmacology & therapeutics.
[91] M. Pirmohamed,et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.
[92] Paul D. Martin,et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.
[93] T. Abe,et al. Comparative Inhibitory Effects of Different Compounds on Rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-Mediated Transport , 2002, Pharmaceutical Research.
[94] J. Donovan,et al. Olanzapine Penetration into Brain is Greater in Transgenic Abcb1a P-glycoprotein-Deficient Mice than FVB1 (Wild-Type) Animals , 2004, Neuropsychopharmacology.
[95] David S. Broomhead,et al. Sensitivity analysis of parameters controlling oscillatory signalling in the NF-/sub K/Bpathway: the roles of IKK and I/sub K/B/sub alpha/ , 2004 .
[96] Kwang-Jin Kim,et al. Role of P-Glycoprotein in Restricting Propranolol Transport in Cultured Rabbit Conjunctival Epithelial Cell Layers , 2000, Pharmaceutical Research.
[97] Ismael Zamora,et al. pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions , 2003, Pharmaceutical Research.
[98] M. Okuda,et al. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). , 2004, European journal of pharmacology.
[99] R. Brereton,et al. Handbook of chemoinformatics: from data to knowledge, edited by Johann Gasteiger, Volumes 1–4. Wiley‐VCH, Weinheim, 2003, ISBN 3527306803, €485 , 2004 .
[100] Kiaran Kirk,et al. The malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily. , 2004, Molecular biology and evolution.
[101] Maristela Lika Onozato,et al. Interactions of Human Organic Anion Transporters with Diuretics , 2004, Journal of Pharmacology and Experimental Therapeutics.
[102] D. Broomhead,et al. Sensitivity analysis of parameters controlling oscillatory signalling in the NFk B pathway : the roles of IKK and I k B a , 2004 .
[103] M. Lazdunski,et al. TREK‐1, a K+ channel involved in neuroprotection and general anesthesia , 2004, The EMBO journal.
[104] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[105] B. Antkowiak,et al. Molecular and systemic mechanisms of general anaesthesia: the ‘multi-site and multiple mechanisms’ concept , 2005, Current opinion in anaesthesiology.
[106] R. Harris,et al. Sites of alcohol and volatile anesthetic action on glycine receptors. , 2005, International review of neurobiology.
[107] A S Verkman,et al. Aquaporin‐3 functions as a glycerol transporter in mammalian skin , 2005, Biology of the cell.
[108] Wolfgang Löscher,et al. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.
[109] Dan S. Tawfik,et al. The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.
[110] Tudor I. Oprea,et al. Chemoinformatics in drug discovery , 2005 .
[111] H. Kusuhara,et al. FUNCTIONAL INVOLVEMENT OF RAT ORGANIC ANION TRANSPORTER 2 (SLC22A7) IN THE HEPATIC UPTAKE OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG KETOPROFEN , 2005, Drug Metabolism and Disposition.
[112] Alfred H. Schinkel,et al. Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.
[113] J. Greef,et al. Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.
[114] S. Bagnasco. Role and regulation of urea transporters , 2005, Pflügers Archiv.
[115] Simon K. Mencher,et al. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) , 2005, BMC clinical pharmacology.
[116] C. Orengo,et al. Protein families and their evolution-a structural perspective. , 2005, Annual review of biochemistry.
[117] Y. Sai,et al. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. , 2005, Drug metabolism and pharmacokinetics.
[118] A. Fliri,et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.
[119] Mariël Brok,et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.
[120] J. Ioannidis. Why Most Published Research Findings Are False , 2005, PLoS medicine.
[121] Michael C Sanguinetti,et al. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.
[122] H. Koepsell,et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. , 2005, American journal of respiratory cell and molecular biology.
[123] K. Poole. Efflux-mediated antimicrobial resistance. , 2005, The Journal of antimicrobial chemotherapy.
[124] H. D. de Koning,et al. Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. , 2005, FEMS microbiology reviews.
[125] H. Schweizer,et al. Bacterial resistance to antibiotics: active efflux and reduced uptake. , 2005, Advanced drug delivery reviews.
[126] Douglas B. Kell,et al. The role of modeling in systems biology , 2005 .
[127] H. Ishiguro,et al. Mechanisms of bicarbonate secretion in the pancreatic duct. , 2005, Annual review of physiology.
[128] Dan S. Tawfik,et al. Enzyme promiscuity: evolutionary and mechanistic aspects. , 2006, Current opinion in chemical biology.
[129] Douglas B Kell,et al. Theodor Bücher Lecture. Metabolomics, modelling and machine learning in systems biology - towards an understanding of the languages of cells. Delivered on 3 July 2005 at the 30th FEBS Congress and the 9th IUBMB conference in Budapest. , 2006, The FEBS journal.
[130] D. Putt,et al. Membrane transport function in primary cultures of human proximal tubular cells. , 2006, Toxicology.
[131] V. Alibu,et al. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. , 2006, Molecular and biochemical parasitology.
[132] Serena M. Bagnasco,et al. The Erythrocyte Urea Transporter UT-B , 2006, The Journal of Membrane Biology.
[133] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[134] W. Boron,et al. Evidence that aquaporin 1 is a major pathway for CO2 transport across the human erythrocyte membrane , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[135] N. Franks,et al. Molecular targets underlying general anaesthesia , 2006, British journal of pharmacology.
[136] Sean Ekins,et al. Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.
[137] Y. Sawada,et al. Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4 , 2006, The Journal of pharmacy and pharmacology.
[138] Dimitris K Agrafiotis,et al. A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set , 2006, Chemical biology & drug design.
[139] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[140] D. Kell. Systems biology, metabolic modelling and metabolomics in drug discovery and development. , 2006, Drug discovery today.
[141] S. Croft,et al. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[142] B. Antkowiak,et al. Anaesthetic drugs: linking molecular actions to clinical effects. , 2006, Current pharmaceutical design.
[143] Christopher J Endres,et al. The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[144] Michael J Sutcliffe,et al. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome , 2006, Expert opinion on drug metabolism & toxicology.
[145] W. Pardridge. Molecular Trojan horses for blood-brain barrier drug delivery. , 2006, Discovery medicine.
[146] P. Imming,et al. Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.
[147] A. Kastrati,et al. Impact of P‐glycoprotein on clopidogrel absorption , 2006, Clinical pharmacology and therapeutics.
[148] R. Kim,et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.
[149] Kathleen Barnes,et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. , 2006, American journal of respiratory and critical care medicine.
[150] J. Donovan,et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein , 2006, Psychopharmacology.
[151] G. Burckhardt,et al. Organic Anion Transporters of the SLC22 Family: Biopharmaceutical, Physiological, and Pathological Roles , 2007, Pharmaceutical Research.
[152] Praveen M. Bahadduri,et al. Rapid Identification of P-glycoprotein Substrates and Inhibitors , 2006, Drug Metabolism and Disposition.
[153] V. Vallon,et al. Decreased Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic Anions in OAT1 Knock-out Mice* , 2006, Journal of Biological Chemistry.
[154] K. Maeda,et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.
[155] R. Alberty,et al. Relations between biochemical thermodynamics and biochemical kinetics. , 2006, Biophysical chemistry.
[156] Douglas B. Kell,et al. Statistical strategies for avoiding false discoveries in metabolomics and related experiments , 2007, Metabolomics.
[157] Nathan Brown,et al. A Chemoinformatics Analysis of Hit Lists Obtained from High-Throughput Affinity-Selection Screening , 2006, Journal of biomolecular screening.
[158] G. Sachs,et al. Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.
[159] K. Maeda,et al. INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS , 2006, Drug Metabolism and Disposition.
[160] B. Palsson. Systems Biology: Properties of Reconstructed Networks , 2006 .
[161] Katsuhisa Inoue,et al. Glycerol uptake in HCT-15 human colon cancer cell line by Na(+)-dependent carrier-mediated transport. , 2006, Biological & pharmaceutical bulletin.
[162] J. Keelan,et al. Active transport across the human placenta: impact on drug efficacy and toxicity , 2006, Expert opinion on drug metabolism & toxicology.
[163] Xiaomin Luo,et al. TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..
[164] D. Kell. Metabolomics, modelling and machine learning in systems biology – towards an understanding of the languages of cells , 2006, The FEBS journal.
[165] Christine Williams,et al. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. , 2007, Journal of pharmacological and toxicological methods.
[166] M. Totrov,et al. Waltzing transporters and 'the dance macabre' between humans and bacteria , 2007, Nature Reviews Drug Discovery.
[167] J. Lima. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. , 2007, Molecular diagnosis & therapy.
[168] Osamu Ogawa,et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.
[169] P. Hardenbol,et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.
[170] R. Krauss,et al. When good drugs go bad , 2007, Nature.
[171] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[172] A. Wanner,et al. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. , 2007, The Journal of allergy and clinical immunology.
[173] V. Bellofatto. Pyrimidine transport activities in trypanosomes. , 2007, Trends in parasitology.
[174] P. Jeffrey,et al. Challenges for blood–brain barrier (BBB) screening , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[175] C. Xia,et al. Evaluation of drug-transporter interactions using in vitro and in vivo models. , 2007, Current drug metabolism.
[176] E. Bertaccini,et al. The Common Chemical Motifs Within Anesthetic Binding Sites , 2007, Anesthesia and analgesia.
[177] T. Terasaki,et al. Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development , 2007, Pharmaceutical Research.
[178] M. Waring,et al. A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.
[179] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[180] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[181] Per Artursson,et al. Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.
[182] P. Prasad,et al. Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate. , 2007, International journal of pharmaceutics.
[183] D. Labuda,et al. Subcellular proteomics of cell differentiation: Quantitative analysis of the plasma membrane proteome of Caco‐2 cells , 2007, Proteomics.
[184] O. Demin,et al. The Edinburgh human metabolic network reconstruction and its functional analysis , 2007, Molecular systems biology.
[185] P. Clemons,et al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.
[186] S. Meshnick,et al. The Mitochondrion Is a Site of Trypanocidal Action of the Aromatic Diamidine DB75 in Bloodstream Forms of Trypanosoma brucei , 2007, Antimicrobial Agents and Chemotherapy.
[187] Xiaomin Luo,et al. PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.
[188] Douglas B Kell,et al. The virtual human: Towards a global systems biology of multiscale, distributed biochemical network models , 2007, IUBMB life.
[189] L. Hamm,et al. Molecular mechanisms of renal ammonia transport. , 2007, Annual review of physiology.
[190] Monica L. Mo,et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.
[191] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[192] S. Lowes,et al. The Contribution of Organic Anion Transporters OAT1 and OAT3 to the Renal Uptake of Rosuvastatin , 2007, Journal of Pharmacology and Experimental Therapeutics.
[193] D. Broomhead,et al. Something from nothing − bridging the gap between constraint‐based and kinetic modelling , 2007, The FEBS journal.
[194] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[195] Richard Morphy,et al. Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.
[196] F. Russel,et al. Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport , 2007, Journal of Pharmacology and Experimental Therapeutics.
[197] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[198] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[199] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[200] M. Leboyer,et al. Pharmacogenetic study of atypical antipsychotic drug response: Involvement of the norepinephrine transporter gene , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[201] T. Iwatsubo,et al. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[202] J. Leppänen,et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. , 2008, Journal of medicinal chemistry.
[203] Robert B. Russell,et al. SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..
[204] J. Nutt,et al. Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.
[205] N. Franks. General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal , 2008, Nature Reviews Neuroscience.
[206] Hong-Bin Chen,et al. Development of a New Predictive Model for Interactions with Human Cytochrome P450 2A6 Using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) Approach , 2009, Pharmaceutical Research.
[207] Douglas B Kell,et al. Proximate parameter tuning for biochemical networks with uncertain kinetic parameters. , 2008, Molecular bioSystems.
[208] A. Małecki,et al. Physiology and pharmacological role of the blood-brain barrier. , 2008, Pharmacological reports : PR.
[209] S. Baker,et al. Interaction of Imatinib with Human Organic Ion Carriers , 2008, Clinical Cancer Research.
[210] A. Cavalli,et al. Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Current Potassium Channel Simulations , 2008, ChemMedChem.
[211] F. Russel,et al. Mechanisms of renal anionic drug transport. , 2008, European journal of pharmacology.
[212] J A Peters,et al. Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.
[213] Antony J. Williams,et al. A perspective of publicly accessible/open-access chemistry databases. , 2008, Drug discovery today.
[214] V. Vallon,et al. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. , 2008, American journal of physiology. Renal physiology.
[215] Markus J. Herrgård,et al. A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology , 2008, Nature Biotechnology.
[216] W. Geldenhuys,et al. Carrier-Mediated Transport of the Quaternary Ammonium Neuronal Nicotinic Receptor Antagonist N,N′-Dodecylbispicolinium Dibromide at the Blood-Brain Barrier , 2008, Journal of Pharmacology and Experimental Therapeutics.
[217] B. Priest,et al. Role of hERG potassium channel assays in drug development , 2008, Channels.
[218] Alan Stobie,et al. Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity. , 2008, Bioorganic & medicinal chemistry letters.
[219] Mark A. Girolami,et al. Bayesian ranking of biochemical system models , 2008, Bioinform..
[220] D. Kell,et al. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.
[221] Antony J Williams,et al. Internet-based tools for communication and collaboration in chemistry. , 2008, Drug discovery today.
[222] Markus J. Herrgård,et al. Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.
[223] Christophe Maurel,et al. Plant aquaporins: membrane channels with multiple integrated functions. , 2008, Annual review of plant biology.
[224] Christel A. S. Bergström,et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. , 2008, Journal of medicinal chemistry.
[225] MB Kelz,et al. From Anesthetic Mechanisms Research to Drug Discovery , 2008, Clinical pharmacology and therapeutics.
[226] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[227] Magnus Rattray,et al. Bayesian inference of the sites of perturbations in metabolic pathways via Markov chain Monte Carlo , 2008, Bioinform..
[228] I. Kola,et al. The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.
[229] Fei He,et al. Sensitivity analysis and robust experimental design of a signal transduction pathway system , 2008 .
[230] Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. , 2008, Trends in parasitology.
[231] Pascale Anderle,et al. Transporter and ion channel gene expression after caco-2 cell differentiation using 2 different microarray technologies , 2004, The AAPS Journal.
[232] D. Hoyle,et al. Identification and characterization of high-flux-control genes of yeast through competition analyses in continuous cultures , 2008, Nature Genetics.
[233] M. Roberts,et al. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. , 2008, FEMS microbiology letters.
[234] Matteo Masetti,et al. Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Current Potassium Channel Simulations , 2008, ChemMedChem.
[235] D. Kell. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases , 2008, BMC Medical Genomics.
[236] J. Mestres,et al. A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.
[237] K. Inui,et al. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). , 2008, Biochemical pharmacology.
[238] B. Orser,et al. GABAA receptor subtypes underlying general anesthesia , 2008, Pharmacology Biochemistry and Behavior.
[239] Mark A. Girolami,et al. Bayesian ranking of biochemical system models , 2008, Bioinform..
[240] P. Artursson,et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[241] A. Y. Lu,et al. The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters. , 2008, Current drug metabolism.
[242] H. Schiöth,et al. The solute carrier (SLC) complement of the human genome: Phylogenetic classification reveals four major families , 2008, FEBS letters.
[243] Steve Pettifer,et al. Defrosting the Digital Library: Bibliographic Tools for the Next Generation Web , 2008, PLoS Comput. Biol..
[244] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[245] E. Poluzzi,et al. The hERG K+ channel: target and antitarget strategies in drug development. , 2008, Pharmacological research.
[246] Jamie I Vandenberg,et al. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. , 2008, Progress in biophysics and molecular biology.
[247] Janet M. Thornton,et al. PROCOGNATE: a cognate ligand domain mapping for enzymes , 2007, Nucleic Acids Res..
[248] Saltelli Andrea,et al. Global Sensitivity Analysis: The Primer , 2008 .
[249] J. Weinstein,et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters , 2008, Molecular Cancer Therapeutics.
[250] Mikko Gynther,et al. Prodrug Approaches for CNS Delivery , 2008, The AAPS Journal.
[251] A. Dalpiaz,et al. Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach , 2008, Molecules.
[252] Katsuhisa Inoue,et al. Functional characterization of human aquaporin 9 as a facilitative glycerol carrier. , 2008, Drug metabolism and pharmacokinetics.
[253] H. McLeod,et al. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. , 2009, Pharmacogenomics.
[254] R. Koch,et al. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug , 2009, Haematologica.
[255] Bin Chen,et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..
[256] R. Kim,et al. Blood−brain barrier transporters and response to CNS-active drugs , 2009, European Journal of Clinical Pharmacology.
[257] C. Saccar. The pharmacology of esomeprazole and its role in gastric acid related diseases , 2009, Expert opinion on drug metabolism & toxicology.
[258] H. Daniel,et al. High-Affinity Interaction of Sartans with H+/Peptide Transporters , 2009, Drug Metabolism and Disposition.
[259] L. Daws. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. , 2009, Pharmacology & therapeutics.
[260] M. Niemi,et al. Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.
[261] Kirsi Vähäkangas,et al. Drug transporters in the human blood‐placental barrier , 2009, British journal of pharmacology.
[262] R. Solé,et al. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.
[263] L. Varatharajan,et al. The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research , 2009, Antiviral research.
[264] J. Mestres,et al. Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.
[265] Ruedi Aebersold,et al. Analysis of Cell Surface Proteome Changes via Label-free, Quantitative Mass Spectrometry*S , 2009, Molecular & Cellular Proteomics.
[266] Y. Sugiyama,et al. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.
[267] Y. Kato,et al. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. , 2009, Journal of pharmaceutical sciences.
[268] M. Pirmohamed,et al. Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes , 2009, PloS one.
[269] Michael J. Keiser,et al. Off-target networks derived from ligand set similarity. , 2009, Methods in molecular biology.
[270] P. Neuvonen,et al. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.
[271] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[272] Andrew L. Hopkins,et al. Predicting promiscuity , 2009 .
[273] L. Bunch,et al. Excitatory amino acid transporters as potential drug targets , 2009, Expert opinion on therapeutic targets.
[274] D. Kell,et al. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. , 2009, Drug discovery today.
[275] C. Gattass,et al. Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1). , 2009, Journal of medicinal chemistry.
[276] Andrew L. Hopkins,et al. Drug discovery: Predicting promiscuity , 2009, Nature.
[277] D. Rees,et al. ABC transporters: the power to change , 2009, Nature Reviews Molecular Cell Biology.
[278] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[279] Maurizio Recanatini,et al. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.
[280] S. Masuda,et al. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. , 2009, Biochemical pharmacology.
[281] Leslie Z. Benet,et al. The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.
[282] Douglas B Kell,et al. Implications of the dominant role of transporters in drug uptake by cells. , 2009, Current topics in medicinal chemistry.
[283] G. Chakravarty,et al. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. , 2009, Biological & pharmaceutical bulletin.
[284] R. Gabathuler. Blood-brain barrier transport of drugs for the treatment of brain diseases. , 2009, CNS & neurological disorders drug targets.
[285] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[286] Ravi Iyengar,et al. Network analyses in systems pharmacology , 2009, Bioinform..
[287] Angelo D. Favia,et al. Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.
[288] Gerhard F. Ecker,et al. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers , 2009, Molecular Diversity.
[289] S. Alper. Molecular physiology and genetics of Na+-independent SLC4 anion exchangers , 2009, Journal of Experimental Biology.
[290] Thierry Lavé,et al. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[291] Ravi Iyengar,et al. Systems pharmacology and genome medicine: a future perspective , 2009, Genome Medicine.
[292] Lin He,et al. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome , 2009, Nucleic Acids Res..
[293] M. Milik,et al. Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.
[294] Y. Karamanos,et al. Understanding the blood–brain barrier using gene and protein expression profiling technologies , 2009, Brain Research Reviews.
[295] Sara Eyal,et al. Drug interactions at the blood-brain barrier: fact or fantasy? , 2009, Pharmacology & therapeutics.
[296] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[297] M. Jamei,et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.
[298] P. Wellendorph,et al. Molecular Pharmacology of Promiscuous Seven Transmembrane Receptors Sensing Organic Nutrients , 2009, Molecular Pharmacology.
[299] M. Fromm,et al. Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala>Ser , 2009, Drug Metabolism and Disposition.
[300] J. Lima,et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response , 2009, Pharmacogenetics and genomics.
[301] D. Kell,et al. The cellular uptake of pharmaceutical drugs is mainly carrier-mediated and is thus an issue not so much of biophysics but of systems biology , 2009 .
[302] J. Leppänen,et al. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. , 2009, Journal of medicinal chemistry.
[303] Charles Elkan,et al. The Transporter Classification Database: recent advances , 2008, Nucleic Acids Res..
[304] Marisa Wong Medina,et al. Pharmacogenomic Discovery Using Cell-Based Models , 2009, Pharmacological Reviews.
[305] D. Kell,et al. Calling International Rescue: knowledge lost in literature and data landslide! , 2009, The Biochemical journal.
[306] Keunwan Park,et al. Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. , 2009, Molecular bioSystems.
[307] Albert J R Heck,et al. Revealing promiscuous drug-target interactions by chemical proteomics. , 2009, Drug discovery today.
[308] M. Morris,et al. The Drug of Abuse γ-Hydroxybutyrate Is a Substrate for Sodium-Coupled Monocarboxylate Transporter (SMCT) 1 (SLC5A8): Characterization of SMCT-Mediated Uptake and Inhibition , 2009, Drug Metabolism and Disposition.
[309] Nigel Greene,et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.
[310] M. Uhlén,et al. Endogenous Gene and Protein Expression of Drug-Transporting Proteins in Cell Lines Routinely Used in Drug Discovery Programs , 2009, Drug Metabolism and Disposition.
[311] K. Brooks,et al. Multiple Genetic Mechanisms Lead to Loss of Functional TbAT1 Expression in Drug-Resistant Trypanosomes , 2009, Eukaryotic Cell.
[312] Sarath Chandra Janga,et al. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. , 2009, Molecular bioSystems.
[313] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[314] S. Landfear,et al. Two novel nucleobase/pentamidine transporters from Trypanosoma brucei. , 2009, Molecular and biochemical parasitology.
[315] Russ B. Altman,et al. Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.
[316] M. Varma,et al. Targeting intestinal transporters for optimizing oral drug absorption. , 2010, Current drug metabolism.
[317] Azeem Majeed,et al. Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009 , 2010, Journal of the Royal Society of Medicine.
[318] Paul D. Leeson,et al. Reducing the Risk of Drug Attrition Associated with Physicochemical Properties , 2010 .
[319] Shiew-Mei Huang,et al. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. , 2010, Toxicology and applied pharmacology.
[320] Alejandro Llanos-Cuentas,et al. Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes , 2010, Proceedings of the National Academy of Sciences.
[321] B. Hagenbuch. Drug Uptake Systems in Liver and Kidney: A Historic Perspective , 2010, Clinical pharmacology and therapeutics.
[322] Dora Brites,et al. Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches , 2010, Brain Research Reviews.
[323] Y. Hagos,et al. Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced Nephrotoxicity , 2010, Toxins.
[324] David N. LeBard,et al. Multiple binding sites for the general anesthetic isoflurane identified in the nicotinic acetylcholine receptor transmembrane domain , 2010, Proceedings of the National Academy of Sciences.
[325] E. Wiemer,et al. Drug Transporters and Imatinib Treatment: Implications for Clinical Practice , 2010, Clinical Cancer Research.
[326] M. Hohenegger,et al. Double impact on p‐glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells , 2009, International journal of cancer.
[327] K M Giacomini,et al. The International Transporter Consortium: A Collaborative Group of Scientists From Academia, Industry, and the FDA , 2010, Clinical pharmacology and therapeutics.
[328] Bradley L Urquhart,et al. Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins , 2010, Circulation research.
[329] F. Russel,et al. Therapeutic implications of renal anionic drug transporters. , 2010, Pharmacology & therapeutics.
[330] R. Kim,et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. , 2010, American journal of physiology. Renal physiology.
[331] S. Zeng,et al. Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers. , 2009, Chirality.
[332] R. Gabathuler,et al. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.
[333] Hong-Jian Zhu,et al. Proteomics Profiling of Madin-Darby Canine Kidney Plasma Membranes Reveals Wnt-5a Involvement during Oncogenic H-Ras/TGF-β-mediated Epithelial-Mesenchymal Transition* , 2010, Molecular & Cellular Proteomics.
[334] Rowena E. Martin,et al. Functional characteristics of the malaria parasite's "chloroquine resistance transporter": Implications for chemotherapy , 2010, Virulence.
[335] D. Thwaites,et al. Hijacking solute carriers for proton-coupled drug transport. , 2010, Physiology.
[336] S. Muresan,et al. Investigation of the relationship between topology and selectivity for druglike molecules. , 2010, Journal of medicinal chemistry.
[337] A. Sali,et al. Comparison of human solute carriers , 2010, Protein science : a publication of the Protein Society.
[338] W. Geldenhuys,et al. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. , 2010, Bioorganic & medicinal chemistry letters.
[339] Shiew-Mei Huang,et al. Pharmacogenomics and adverse drug reactions. , 2010, Personalized medicine.
[340] K. Maeda,et al. The use of hepatocytes to investigate drug uptake transporters. , 2010, Methods in molecular biology.
[341] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[342] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[343] Kevin Y. Yip,et al. Extensive In Vivo Metabolite-Protein Interactions Revealed by Large-Scale Systematic Analyses , 2010, Cell.
[344] R. Iyengar,et al. Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.
[345] C. Bosquillon,et al. Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs? , 2010, Journal of pharmaceutical sciences.
[346] P. Hajduk,et al. Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. , 2010, Current opinion in chemical biology.
[347] W. Geldenhuys,et al. Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules. , 2010, Therapeutic delivery.
[348] Navdeep Jaitly,et al. A Structure-Based Approach for Mapping Adverse Drug Reactions to the Perturbation of Underlying Biological Pathways , 2010, PloS one.
[349] A. D. Rodrigues,et al. Enzyme- and transporter-based drug-drug Interactions : progress and future challenges , 2010 .
[350] B. Barres,et al. The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells , 2010, PloS one.
[351] Dan S. Tawfik,et al. Enzyme promiscuity: a mechanistic and evolutionary perspective. , 2010, Annual review of biochemistry.
[352] E. Boulpaep,et al. Substrate specificity of Rhbg: ammonium and methyl ammonium transport. , 2010, American journal of physiology. Cell physiology.
[353] Jürgen Bajorath,et al. Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs , 2010, J. Chem. Inf. Model..
[354] J. Leppänen,et al. Brain uptake of ketoprofen-lysine prodrug in rats. , 2010, International journal of pharmaceutics.
[355] M. Niemi. Transporter Pharmacogenetics and Statin Toxicity , 2010, Clinical pharmacology and therapeutics.
[356] A Rostami-Hodjegan,et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.
[357] B. Gerrits,et al. Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. , 2010, Blood.
[358] David J. Begley,et al. Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.
[359] John P. Overington,et al. Role of open chemical data in aiding drug discovery and design. , 2010, Future medicinal chemistry.
[360] Shehab Mahmoud,et al. Brain‐Specific Delivery of Naproxen Using Different Carrier Systems , 2010, Archiv der Pharmazie.
[361] A. D. Rodrigues,et al. Enzyme- and transporter-based drug-drug Interaction , 2010 .
[362] Andrew Jenkins,et al. General Anesthetic Actions on GABAA Receptors , 2010, Current neuropharmacology.
[363] Jordi Mestres,et al. Anticipating drug side effects by comparative pharmacology , 2010, Expert opinion on drug metabolism & toxicology.
[364] M. Waring. Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.
[365] S. Bernèche,et al. Transport mechanisms in the ammonium transporter family. , 2010, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.
[366] Leslie Z Benet,et al. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. , 2010, Basic & clinical pharmacology & toxicology.
[367] E. Lundberg,et al. Creation of an antibody‐based subcellular protein atlas , 2010, Proteomics.
[368] E. Bates,et al. Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count? , 2010, Pharmacotherapy.
[369] Li Di,et al. Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.
[370] D. Venzon,et al. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. , 2010, Pharmacogenomics.
[371] Frans G. M. Russel,et al. Transporters: Importance in Drug Absorption, Distribution, and Removal , 2010 .
[372] David S. Wishart,et al. T3DB: a comprehensively annotated database of common toxins and their targets , 2009, Nucleic Acids Res..
[373] SRB Allerheiligen,et al. Next‐Generation Model‐Based Drug Discovery and Development: Quantitative and Systems Pharmacology , 2010, Clinical pharmacology and therapeutics.
[374] Yuichi Sugiyama,et al. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[375] M. Fromm,et al. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects , 2010, Drug metabolism reviews.
[376] Ines Thiele,et al. Reconstruction annotation jamborees: a community approach to systems biology , 2010, Molecular systems biology.
[377] Tudor I. Oprea,et al. iPHACE: integrative navigation in pharmacological space , 2010, Bioinform..
[378] S. Bryant,et al. PubChem as a public resource for drug discovery. , 2010, Drug discovery today.
[379] Yoshihiro Yamanishi,et al. Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.
[380] Douglas B. Kell,et al. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples , 2010, Archives of Toxicology.
[381] R. Bendayan,et al. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. , 2010, Trends in pharmacological sciences.
[382] T. Kusaka,et al. Transporters in the brain endothelial barrier. , 2010, Current medicinal chemistry.
[383] M. Sanguinetti,et al. SYMPOSIUM REVIEW: Revealing the structural basis of action of hERG potassium channel activators and blockers , 2010, The Journal of physiology.
[384] Christoph Steinbeck,et al. Chemical Entities of Biological Interest: an update , 2009, Nucleic Acids Res..
[385] Wandong Zhang,et al. ABC Transporters and Drug Efflux at the Blood-Brain Barrier , 2010, Reviews in the neurosciences.
[386] M. Gionfriddo,et al. Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. , 2009, Biopharmaceutics & drug disposition.
[387] Sean Ekins,et al. Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. , 2010, Molecular pharmaceutics.
[388] Olga Khersonsky,et al. 8.03 – Enzyme Promiscuity – Evolutionary and Mechanistic Aspects , 2010 .
[389] E. Lundberg,et al. Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.
[390] P. Aloy,et al. Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.
[391] A. Rodrigues. Efflux and uptake transporters as determinants of statin response , 2010, Expert opinion on drug metabolism & toxicology.
[392] Michael J. Keiser,et al. The Chemical Basis of Pharmacology , 2010, Biochemistry.
[393] A. Avdeef,et al. Physicochemical Selectivity of the BBB Microenvironment Governing Passive Diffusion—Matching with a Porcine Brain Lipid Extract Artificial Membrane Permeability Model , 2011, Pharmaceutical Research.
[394] Pär Matsson,et al. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. , 2011, Journal of medicinal chemistry.
[395] M. Fromm,et al. Transporter‐Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.
[396] R. Franke,et al. Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. , 2011, Experimental hematology.
[397] Avner Schlessinger,et al. Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET , 2011, Proceedings of the National Academy of Sciences.
[398] Katsuhisa Inoue,et al. Dual Functional Characteristic of Human Aquaporin 10 for Solute Transport , 2011, Cellular Physiology and Biochemistry.
[399] T. Thompson. The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions , 2011 .
[400] Jürgen Bajorath,et al. Mapping of pharmacological space , 2011, Expert opinion on drug discovery.
[401] Flemming Steen Jørgensen,et al. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. , 2011, Combinatorial chemistry & high throughput screening.
[402] Stephen P. H. Alexander,et al. Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.
[403] R. Iyengar,et al. Systems pharmacology of complex diseases , 2011, Annals of the New York Academy of Sciences.
[404] D. Horn,et al. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6 , 2011, Molecular and biochemical parasitology.
[405] Tudor I. Oprea,et al. BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.
[406] J. Verlander,et al. Role of NH3 and NH4+ transporters in renal acid-base transport. , 2011, American journal of physiology. Renal physiology.
[407] Li Hai,et al. Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen. , 2011, European journal of medicinal chemistry.
[408] Yoichi Kameda,et al. Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy , 2012, Annals of Surgical Oncology.
[409] Alfons Nonell-Canals,et al. In Silico Target Profiling of One Billion Molecules , 2011, Molecular informatics.
[410] J. Polli,et al. Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2. , 2011, Journal of pharmaceutical sciences.
[411] T. Wellems,et al. Malaria drug resistance: new observations and developments. , 2011, Essays in biochemistry.
[412] F. Van Bambeke,et al. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. , 2011, Current drug targets.
[413] G. Ciarimboli. Role of organic cation transporters in drug-induced toxicity , 2011, Expert opinion on drug metabolism & toxicology.
[414] A. Yonezawa,et al. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics , 2011, British journal of pharmacology.
[415] R. Tirona. Molecular mechanisms of drug transporter regulation. , 2011, Handbook of experimental pharmacology.
[416] Philip E. Bourne,et al. PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..
[417] H. Bayley,et al. Fluorinated amphiphiles control the insertion of α-hemolysin pores into lipid bilayers. , 2011, Biochemistry.
[418] J. Leppänen,et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. , 2011, Molecular pharmaceutics.
[419] J. Kehr,et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study , 2011, Journal of psychopharmacology.
[420] Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments. , 2011, Current drug metabolism.
[421] P. Dawson. Role of the intestinal bile acid transporters in bile acid and drug disposition. , 2011, Handbook of experimental pharmacology.
[422] A. R. Fernandes,et al. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1 , 2011, Leukemia & lymphoma.
[423] T. Abe,et al. Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. , 2011, Biological & pharmaceutical bulletin.
[424] Isabel M. Vincent,et al. Drug resistance in human African trypanosomiasis. , 2011, Future microbiology.
[425] P. Neuvonen,et al. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.
[426] M. Fromm,et al. Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs , 2011, Pharmaceutics.
[427] Sang Yup Lee,et al. Systems metabolic engineering for chemicals and materials. , 2011, Trends in biotechnology.
[428] C. Cheng,et al. Drug transporters and blood--testis barrier function. , 2011, The Journal of endocrinology.
[429] Yibo Wang,et al. Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. , 2011, American journal of hypertension.
[430] A. Wanner,et al. Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway. , 2011, Pulmonary pharmacology & therapeutics.
[431] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[432] Bernhard O. Palsson,et al. The human metabolic reconstruction Recon 1 directs hypotheses of novel human metabolic functions , 2011, BMC Systems Biology.
[433] A. Bjorkman,et al. Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America , 2011, Malaria Journal.
[434] P. Roepe. PfCRT-mediated drug transport in malarial parasites. , 2011, Biochemistry.
[435] M. Kennedy,et al. Clinical Implications of Pharmacogenetic Variation on the Effects of Statins , 2011, Drug safety.
[436] F. Cheng,et al. Insights into Molecular Basis of Cytochrome P450 Inhibitory Promiscuity of Compounds , 2011, J. Chem. Inf. Model..
[437] H. Koepsell,et al. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. , 2011, Handbook of experimental pharmacology.
[438] Isabel Roditi,et al. Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. , 2011, Molecular and biochemical parasitology.
[439] Oleg Demin,et al. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.
[440] Lin He,et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein interactome , 2011, Nucleic Acids Res..
[441] Rowena E. Martin,et al. Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics , 2012, Cellular and Molecular Life Sciences.
[442] K. Ishibashi,et al. The evolutionary aspects of aquaporin family. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.
[443] Douglas B Kell,et al. Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. , 2011, Drug discovery today.
[444] Alejandro Sanchez-Flores,et al. High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome. , 2011, Genome research.
[445] John Higgins,et al. Strategies for bringing drug delivery tools into discovery. , 2011, International journal of pharmaceutics.
[446] Shiew-Mei Huang,et al. Transporter‐Mediated Drug–Drug Interactions , 2011, Clinical pharmacology and therapeutics.
[447] TP Hughes,et al. OCT‐1 as a Determinant of Response to Antileukemic Treatment , 2011, Clinical pharmacology and therapeutics.
[448] G. He,et al. Chemical-protein interactome and its application in off-target identification , 2011, Interdisciplinary Sciences: Computational Life Sciences.
[449] J. Lima,et al. Effect of Citrus Juice and SLCO2B1 Genotype on the Pharmacokinetics of Montelukast , 2011, Journal of clinical pharmacology.
[450] Paul D. Leeson,et al. Impact of ion class and time on oral drug molecular properties , 2011 .
[451] Joshua D. Knowles,et al. Efficient discovery of anti-inflammatory small molecule combinations using evolutionary computing , 2011, Nature chemical biology.
[452] Lei Xie,et al. Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.
[453] A. Tsuji. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems , 2011, NeuroRX.
[454] M. Battegay,et al. Mechanisms of Drug Interactions II: Transport Proteins , 2011 .
[455] P. Houillier,et al. The rhesus protein RhCG: a new perspective in ammonium transport and distal urinary acidification. , 2011, Kidney international.
[456] Tudor I. Oprea,et al. ChemProt: a disease chemical biology database , 2010, Nucleic Acids Res..
[457] D. Thwaites,et al. The SLC36 family of proton‐coupled amino acid transporters and their potential role in drug transport , 2011, British journal of pharmacology.
[458] Z. Ni,et al. ATP-binding cassette efflux transporters in human placenta. , 2011, Current pharmaceutical biotechnology.
[459] Humberto González-Díaz,et al. 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. , 2011, European journal of medicinal chemistry.
[460] T. Terasaki,et al. Functional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriers. , 2011, Journal of pharmaceutical sciences.
[461] Neema Jamshidi,et al. Linkage of Organic Anion Transporter-1 to Metabolic Pathways through Integrated “Omics”-driven Network and Functional Analysis* , 2011, The Journal of Biological Chemistry.
[462] E. Wiemer,et al. Drug transporters of platinum-based anticancer agents and their clinical significance. , 2011, Drug resistance updates.
[463] C. Cametti,et al. On the dielectric relaxation of biological cell suspensions: the effect of the membrane electrical conductivity. , 2011, Colloids and surfaces. B, Biointerfaces.
[464] Norman W. Paton,et al. The SuBliMinaL Toolbox: automating steps in the reconstruction of metabolic networks , 2011, J. Integr. Bioinform..
[465] E. Schneider,et al. ATP binding cassette systems: structures, mechanisms, and functions , 2011, Central European Journal of Biology.
[466] E. Ullu,et al. RNA Interference in Protozoan Parasites: Achievements and Challenges , 2011, Eukaryotic Cell.
[467] J. Changeux,et al. X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel , 2011, Nature.
[468] Douglas B Kell,et al. Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast , 2011, BMC Biology.
[469] Paul D. Leeson,et al. The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.
[470] David W. Ritchie,et al. Using Consensus-Shape Clustering To Identify Promiscuous Ligands and Protein Targets and To Choose the Right Query for Shape-Based Virtual Screening , 2011, J. Chem. Inf. Model..
[471] Katrin Wlcek,et al. Organic anion transporting polypeptides (OATPs): regulation of expression and function. , 2011, Current drug metabolism.
[472] Kim L R Brouwer,et al. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. , 2011, Journal of pharmaceutical sciences.
[473] Neil Benson,et al. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.
[474] G. Stewart. The emerging physiological roles of the SLC14A family of urea transporters , 2011, British journal of pharmacology.
[475] Xiyan Li,et al. Metabolites as global regulators: A new view of protein regulation , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.
[476] M. Fanselow,et al. Inhaled Anesthetic Responses of Recombinant Receptors and Knockin Mice Harboring α2(S270H/L277A) GABAA Receptor Subunits That Are Resistant to Isoflurane , 2011, Journal of Pharmacology and Experimental Therapeutics.
[477] H. Bayley,et al. Controlled translocation of individual DNA molecules through protein nanopores with engineered molecular brakes. , 2011, Nano letters.
[478] F. Theodoulou,et al. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance , 2011, British journal of pharmacology.
[479] D. Kell. Systems biology: Metabolites do social networking. , 2011, Nature chemical biology.
[480] Joseph J. Babcock,et al. Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules , 2011, Acta Pharmacologica Sinica.
[481] Y. Shitara. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. , 2011, Drug metabolism and pharmacokinetics.
[482] C. Cheng,et al. Emerging role for drug transporters at the blood-testis barrier. , 2011, Trends in pharmacological sciences.
[483] K. Maeda,et al. Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments , 2011, Drug Metabolism and Disposition.
[484] Ronan M. T. Fleming,et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.
[485] D. Singh,et al. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani , 2011, Antimicrobial Agents and Chemotherapy.
[486] R. Kim,et al. Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2 , 2011, Clinical pharmacology and therapeutics.
[487] C. Haller,et al. Adverse Drug Reactions: Moving from Chance to Science , 2011, Clinical pharmacology and therapeutics.
[488] S. Pukatzki,et al. Antibiotic resistance mechanisms of Vibrio cholerae. , 2011, Journal of medical microbiology.
[489] Y. Choi,et al. Herb-drug interactions: Focus on metabolic enzymes and transporters , 2011, Archives of pharmacal research.
[490] Seth I. Berger,et al. Role of systems pharmacology in understanding drug adverse events , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.
[491] A. Dalpiaz,et al. Prodrugs and endogenous transporters: are they suitable tools for drug targeting into the central nervous system? , 2011, Current pharmaceutical design.
[492] J. Palomino,et al. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. , 2011, FEMS immunology and medical microbiology.
[493] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[494] Bonaventura Clotet,et al. Drug uptake transporters in antiretroviral therapy. , 2011, Pharmacology & therapeutics.
[495] T. Nakanishi,et al. Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. , 2011, Journal of pharmaceutical sciences.
[496] J. König,et al. Double‐transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations , 2011, British journal of pharmacology.
[497] Ruth Brenk,et al. Mining the ChEMBL Database: An Efficient Chemoinformatics Workflow for Assembling an Ion Channel-Focused Screening Library , 2011, J. Chem. Inf. Model..
[498] Tudor I. Oprea,et al. Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome , 2011, Clinical pharmacology and therapeutics.
[499] T. Terasaki,et al. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. , 2011, Journal of pharmaceutical sciences.
[500] Bryan L Roth,et al. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. , 2011, Annual review of pharmacology and toxicology.
[501] Tudor I. Oprea,et al. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer‐Aided Drug Repurposing , 2011, Molecular informatics.
[502] P. Pohl,et al. Intrinsic CO2 permeability of cell membranes and potential biological relevance of CO2 channels. , 2011, Chemphyschem : a European journal of chemical physics and physical chemistry.
[503] Michael S Lajiness,et al. Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research. , 2012, Drug discovery today.
[504] Tudor I. Oprea,et al. Improving the prediction of the brain disposition for orally administered drugs using BDDCS. , 2012, Advanced drug delivery reviews.
[505] D. Sibley,et al. The Blood-Testis Barrier and Its Implications for Male Contraception , 2012, Pharmacological Reviews.
[506] Horst Kessler,et al. Intestinal permeability of cyclic peptides: common key backbone motifs identified. , 2012, Journal of the American Chemical Society.
[507] B. Hagenbuch,et al. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies , 2012, British journal of pharmacology.
[508] Ruedi Aebersold,et al. Direct identification of ligand-receptor interactions on living cells and tissues , 2012, Nature Biotechnology.
[509] Juliana M. Sá,et al. Functional Characterization of the Plasmodium falciparum Chloroquine-Resistance Transporter (PfCRT) in Transformed Dictyostelium discoideum Vesicles , 2012, PloS one.
[510] J. Venitz,et al. Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters , 2012, Expert opinion on drug metabolism & toxicology.
[511] A. Goffeau,et al. Yeast ATP-binding cassette transporters conferring multidrug resistance. , 2012, Annual review of microbiology.
[512] S. Bates,et al. Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. , 2012, Discovery medicine.
[513] T. Dinan,et al. Inhibition of P‐glycoprotein enhances transport of imipramine across the blood–brain barrier: microdialysis studies in conscious freely moving rats , 2012, British journal of pharmacology.
[514] I. Tamai. Oral drug delivery utilizing intestinal OATP transporters. , 2012, Advanced drug delivery reviews.
[515] David S. Roos,et al. TDR Targets: a chemogenomics resource for neglected diseases , 2011, Nucleic Acids Res..
[516] Alberto Del Rio,et al. Freely accessible databases of commercial compounds for high- throughput virtual screenings. , 2012, Current topics in medicinal chemistry.
[517] B. Feng,et al. Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions , 2012, Pharmaceutical Research.
[518] G. Ecker,et al. Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.
[519] Lihong Liu,et al. Modern methods for delivery of drugs across the blood-brain barrier. , 2012, Advanced drug delivery reviews.
[520] P. Couraud,et al. The involvement of a Na⁺- and Cl⁻-dependent transporter in the brain uptake of amantadine and rimantadine. , 2012, Molecular pharmaceutics.
[521] Bruno Hagenbuch,et al. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. , 2012, Annual review of pharmacology and toxicology.
[522] Norbert Perrimon,et al. RNAi screening: new approaches, understandings, and organisms , 2012, Wiley interdisciplinary reviews. RNA.
[523] Olivier Fardel,et al. Environmental chemicals as substrates, inhibitors or inducers of drug transporters: implication for toxicokinetics, toxicity and pharmacokinetics , 2012, Expert opinion on drug metabolism & toxicology.
[524] H. Glaeser,et al. Interaction of innovative small molecule drugs used for cancer therapy with drug transporters , 2012, British journal of pharmacology.
[525] Patrick R. Griffin,et al. PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem , 2012, Bioinform..
[526] Mathias Dunkel,et al. Binding sites in membrane proteins--diversity, druggability and prospects. , 2012, European journal of cell biology.
[527] Cui Yang,et al. Physiological and Pharmacological Roles of Vascular Nucleoside Transporters , 2012, Journal of cardiovascular pharmacology.
[528] V. Kouznetsova,et al. Organic Anion and Cation SLC22 “Drug” Transporter (Oat1, Oat3, and Oct1) Regulation during Development and Maturation of the Kidney Proximal Tubule , 2012, PloS one.
[529] [System biology and synthetic biology modify drug discovery and development]. , 2012, Medecine sciences : M/S.
[530] O. Taboureau,et al. The impact of network biology in pharmacology and toxicology , 2012, SAR and QSAR in environmental research.
[531] M. Pirmohamed,et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. , 2012, Biochemical pharmacology.
[532] David W Ritchie,et al. Identifying and characterizing promiscuous targets: Implications for virtual screening , 2012, Expert opinion on drug discovery.
[533] P. Neuvonen. Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee. , 2012, Basic & clinical pharmacology & toxicology.
[534] W. Banks. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. , 2012, Advanced drug delivery reviews.
[535] K. Maeda,et al. Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.
[536] Wolfgang Guba,et al. Can we discover pharmacological promiscuity early in the drug discovery process? , 2012, Drug discovery today.
[537] Yang Song,et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..
[538] Sean Ekins,et al. Molecular Determinants of Ligand Selectivity for the Human Multidrug and Toxin Extruder Proteins MATE1 and MATE2-K , 2012, Journal of Pharmacology and Experimental Therapeutics.
[539] H. Barton,et al. In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation , 2012, Drug Metabolism and Disposition.
[540] Ulf Norinder,et al. Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.
[541] L. Tremaine,et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development , 2012, Expert opinion on drug metabolism & toxicology.
[542] A. Rostami-Hodjegan,et al. Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.
[543] C. Ehrhardt,et al. Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. , 2012, Therapeutic delivery.
[544] W. Geldenhuys,et al. The blood-brain barrier choline transporter. , 2012, Central nervous system agents in medicinal chemistry.
[545] Taizo Shiraishi,et al. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3–T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy , 2012, Journal of hepato-biliary-pancreatic sciences.
[546] S. Husain,et al. The Location and Nature of General Anesthetic Binding Sites on the Active Conformation of Firefly Luciferase; A Time Resolved Photolabeling Study , 2012, PloS one.
[547] O. Pantoja. High Affinity Ammonium Transporters: Molecular Mechanism of Action , 2012, Front. Plant Sci..
[548] C. Sempoux,et al. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. , 2012, European journal of cancer.
[549] Gergely Zahoránszky-Köhalmi,et al. Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..
[550] Igor Goryanin,et al. The reconstruction and analysis of tissue specific human metabolic networks. , 2012, Molecular bioSystems.
[551] A. Ferro,et al. Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications , 2012, Clinical Pharmacokinetics.
[552] Mark C. Field,et al. High-throughput decoding of anti-trypanosomal drug efficacy and resistance , 2011, Nature.
[553] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[554] D. Surry,et al. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[555] B. Kemp,et al. The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase , 2012, Science.
[556] A. Mardinoğlu,et al. Systems medicine and metabolic modelling , 2012, Journal of internal medicine.
[557] A. Sparreboom,et al. Contribution of tumoral and host solute carriers to clinical drug response. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[558] A. Mitra,et al. Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. , 2012, Current drug targets.
[559] K. Giacomini,et al. The UCSF‐FDA TransPortal: A Public Drug Transporter Database , 2012, Clinical pharmacology and therapeutics.
[560] A. Ray,et al. Renal drug–drug interactions: what we have learned and where we are going , 2012, Expert opinion on drug metabolism & toxicology.
[561] Paul O'Shea. Future medicine shaped by an interdisciplinary new biology , 2012, The Lancet.
[562] Dong Xu,et al. Protein Databases on the Internet , 2012, Current protocols in molecular biology.
[563] P. Sexton,et al. Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.
[564] W. Geldenhuys,et al. Novel models for assessing blood–brain barrier drug permeation , 2012, Expert opinion on drug metabolism & toxicology.
[565] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[566] J. Brockmöller,et al. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. , 2012, Biochemical pharmacology.
[567] E. van de Steeg,et al. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. , 2012, Trends in pharmacological sciences.
[568] J. Haiech,et al. Biologie des systèmes et ingénierie biologique modifient la découverte et le développement des médicaments , 2012 .
[569] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[570] T. Nakanishi,et al. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. , 2012, Drug metabolism and pharmacokinetics.
[571] Lourdes Cucurull-Sanchez,et al. Relevance of systems pharmacology in drug discovery. , 2012, Drug discovery today.
[572] N. Cherrington,et al. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions , 2012, Expert opinion on drug metabolism & toxicology.
[573] Andrew C Good,et al. Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. , 2012, Journal of medicinal chemistry.
[574] Philip E. Bourne,et al. SuperTarget goes quantitative: update on drug–target interactions , 2011, Nucleic Acids Res..
[575] Sean Ekins,et al. A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. , 2012, Molecular pharmaceutics.
[576] Sarah L. Kinnings,et al. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. , 2012, Annual review of pharmacology and toxicology.
[577] R. Iyengar,et al. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.
[578] Yuko Ohno,et al. Pharmacophore modeling for hERG channel facilitation. , 2012, Biochemical and biophysical research communications.
[579] M. Barrett,et al. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes , 2012, Proceedings of the National Academy of Sciences.
[580] A. Ayrton,et al. Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[581] K. Asami. Dielectric spectroscopy reveals nanoholes in erythrocyte ghosts , 2012 .
[582] Kevan M. Shokat,et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.
[583] Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection , 2012, Annals of surgery.
[584] A Rostami-Hodjegan,et al. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. , 2013, Biopharmaceutics & drug disposition.
[585] Drug Resistance in Leishmania , 2014 .